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Background: Emerging studies indicate that B-type natriuretic peptide (BNP), a well-known biomarker for heart
failure, also plays pivotal roles in metabolic control. Circulating BNP levels progressively increase as ages grow older.
However, the association between BNP levels and lipid metabolism in the elderly remains unknown.
Methods: A total of 680 eligible volunteers (male/female: 334/346) aged between 60 and 80 years old without
overt heart failure (BNP <100 pg/ml) were enrolled. Random nonfasting venous samples were obtained for
biochemical analysis. The subjects were stratified based on BNP quartiles: BNP Q1 (range: 2.2–9.0 pg/ml),
Q2 (9.1–20.4 pg/ml), Q3 (20.5–44.4 pg/ml) and Q4 (44.6–99.7 pg/ml). Difference of metabolic parameters was
compared among the subjects grouped by BNP quartiles. Univariate correlation and multiple linear regression
were performed to analyze the association between BNP levels and metabolic parameters. The odds ratios
(OR) and 95 % confidence intervals (CI) for dyslipidemia in subjects within BNP Q1-3 relative to subjects
within BNP Q4 were calculated.
Results: Circulating BNP levels positively correlated with age, while negatively correlated with body mass index
(BMI), eGFR and non-HDL. Subjects with lower BNP quartiles had significantly elevated prevalence of dyslipidemia,
including hypertriglyceridemia, hyper-LDL-emia and hypercholesterolemia. The OR of hypertriglyceridemia and
hypercholesterolemia for subjects within BNP Q1-2 significantly increased relative to BNP Q4.
Conclusions: The elderly people with higher BNP levels have significantly reduced risks for nonfasting dyslipidemia.
Verification of the cause-effect relationship between BNP and dyslipidemia may bring therapeutic implications.
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Natriuretic peptides (NPs) are a group of functionally
and structurally related peptides, including atrial NP
(ANP), B-type NP (BNP) and C-type NP (CNP). BNP is
predominantly expressed by ventricular cells and corre-
lates better with the severity of heart failure than ANP,
so BNP has gained more intense researches as a clinic-
ally useful biomarker [1, 2].* Correspondence: kandat@kanazawa-med.ac.jp
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(http://creativecommons.org/publicdomain/zeAlthough higher BNP levels are often associated with
adverse cardiovascular outcomes [3, 4], growing evi-
dence has demonstrated that elevated BNP plays benefi-
cial roles in metabolic regulation under non-heart failure
settings. As opposed to cardiac cachexia partly mediated
by raised BNP levels [5, 6], the inverse correlation
between BNP and body mass index (BMI) has been
consistently reported in a number of observational
studies [7–9]. Mechanistically, BNP directly promotes
mitochondrial biogenesis in skeletal muscles and white
adipocytes to enhance energy expenditure [10, 11].
Through these mechanisms, transgenic miceistributed under the terms of the Creative Commons Attribution 4.0
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diet induced obesity, insulin resistance and diabetes [10].
Thus, heart-derived BNP has been viewed as a central
player in the control of body weight and energy
metabolism.
Recently, it has been demonstrated that higher BNP
levels correlate with favorable adiposity profiles, includ-
ing reduced deposition of visceral and liver fat [12]. The
pattern of body fat distribution is an independent factor
associated with metabolic syndrome in the elderly popu-
lation, including dyslipidemia [13]. Therefore, BNP
might affect the lipid metabolism. Schlueter N et al. have
postulated that BNP holds the potential to treat a series
of metabolic disorders [14]. Paradoxically, existing data
also suggest that higher BNP levels provide independ-
ently predictive value on assessment of future cardio-
vascular disease (CVD) risk [3], whereas cholesterol-
lowering rosuvastatin treatment effectively improves
the adverse outcome. In another study, a nonlinear U
relationship between BNP and metabolic syndrome
has been observed [15]. It seems that the influence of
BNP on CVD risks in clinic is far more complicated
than experimental results from transgenic murine
models. However, overexpression of BNP under car-
diac stress belongs per se to a cluster of protectively
compensatory events. Consequently, BNP to a certain
extent benefits cardiac function through generalized
loss of fat tissue in addition to natriuresis. Thus, high
BNP levels might be associated with lipid metabolism.
Nevertheless, the direct data available on this issue
remain lacking.
We hypothesized that BNP might play beneficial roles
in lipid metabolism. To this end, we investigated the as-
sociations between BNP levels and nonfasting lipid levels
in the elderly people without overt heart failure. We
found that the elderly people with higher BNP levels
tended to have reduced prevalence of hypertriglyc-
eridemia, hypercholesterolemia and hyper-LDL-emia,
which supports the beneficial roles of BNP in lipid me-
tabolism. This study was performed based on two major
respects. Firstly, the elderly people have larger variation
range of BNP levels than younger people [16], which
might make the difference in lipid metabolism more vis-
ible. Secondly, emerging evidence supports the notion
that nonfasting lipid levels provide more predictive
values on risks for CVD than fasting lipids in additional to
increased patient compliance. In several large population-
based prospectively observational studies, nonfasting
triglyceride (TAG) has been shown to be a superior risk
predictor for CVD compared with fasting TAG [17, 18].
Nonfasting total cholesterol (TC), low-density lipoprotein
cholesterol (LDL-C) and high-density lipoprotein choles-
terol (HDL-C) change minimally in response to normal
food intake [19].Methods
Study subjects
All subjects who participated in the cross-sectional
research were from community-dwelling residents re-
ceived annual examinations in Himi Municipal Hospital,
Kanazawa Medical University. From Jan 2012 to May
2015, a total of 1248 volunteers who met the following
criteria were enrolled in the study. The inclusion criteria
included: (1) age above 60 and less than 80 years old; (2)
serum Cr levels less than 2 mg/dL; (3) no overt dysfunc-
tion of heart, liver or lung diseases; (4) the level of BNP
between 0 and 100 pg/mL; (5) 0.1 mIU/L ≤ TSH ≤10
mIU/L, FT3 and FT4 within the normal range. As vari-
ous factors affect the levels of BNP and lipids, such as
acute inflammation, injury, thyroid hormones, blood vol-
ume and sex steroids, we excluded those who met the
exclusion criteria, including: (1) acute infection and
stress in the last three months (n = 59); (2) medication
on lipid-lowering drugs, glucocortoids, sex steroids, di-
uretics and thyroid-related drugs (n = 413); (3) overt hyper-
thyroidism or hypothyroidism (n = 96). The remaining 680
participants were involved in this study. Electronic data
on medical history for each participant are accessible in
the computerized database of Himi Municipal Hospital.
All participants provided informed written consent. The
protocols of the study were approved by the Ethics Board
of Kanazawa Medical University Himi Municipal Hospital
(protocol number 34).
Anthropometric measurements
Anthropometric parameters obtained in this study in-
cluded weight, height and BMI. BMI was calculated as
body weight in kilograms divided by the height squared
(kg/m2).
Biochemical investigations
Random venous blood samples were collected in tubes
containing liquid EDTA and were centrifuged to obtain
plasma for further biochemical analysis. Liver and kidney
function tests, UA, TC, HDL-C, LDL-C and TAG were
measured by automated analyzer (JCA-BM6050 Bio
Majesty, Nihon Denshi Co. Ltd., Tokyo, Japan). The
minimal detectable limit of BNP was 2.0 pg/mL. The
mean intra-assay and inter-assay coefficients were 2.1
and 3.6 %, respectively. Non-HDL was defined by the
formula: non-HDL = TC −HDL-C. HbA1c was examined
by a latex coagulation method. BNP levels were mea-
sured using chemiluminescent enzyme immunoassay kit
(MI02 Shionogi BNP; Shionogi Co. Ltd., Osaka, Japan).
The serum thyroid function was measured by chemilu-
minescence assay. The eGFR was calculated by an equa-
tion for Japanese: eGFR (ml/min/1.73 m2) = 194 × Cr-
1.094 × age-0.287 × 0.739 (if female). Currently, there are no
available age- and population-based standards for random
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ference exists between nonfasting and fasting lipid levels
[19]. In this study, definition criteria for abnormal lipid
metabolic indicators were used with reference to the fol-
lowing statement or guideline, including American Heart
Association (AHA) scientific statement on triglycerides
and CVD [17], and American Association of Clinical En-
docrinologists’ Guidelines for Management of Dyslipid-
emia and Prevention of Atherosclerosis (2012) [20].
Specifically, cut-off points for dyslipidemia were defined
as any one of the following: TC ≥200 mg/dL, LDL-
C ≥130 mg/dL, HDL-C ≤60 mg/dL or TAG ≥200 mg/dL.
Statistical analysis
The study population was separated into four groups ac-
cording to BNP quartiles, namely BNP Q1-Q4. The nor-
mality of distribution was performed by Kolmogorov-
Smirnov test. Variables with skewed distribution were
expressed as median and quartile ranges (25th to 75th
percentiles). Continuous variables with normal distribu-
tion were expressed as mean ± standard deviation (SD).
Categorical variables were expressed as numbers and
percentages. Chi-square test was used to compare cat-
egorical variables. The difference of variables among dif-
ferent BNP categories was compared by One-Way
ANOVA test, and then Student-Newman-Keuls pairwise
comparisons were performed if P <0.05. Difference of
BNP levels in subjects with normal and abnormal lipids
was analyzed by Mann–Whitney U test. Univariate asso-
ciation between BNP and continuous variables was
expressed as Spearman’s correlation coefficients. Values
were transformed to the log base of 10 to obtain stand-
ard normal variables if needed. Stepwise multiple linear
regression was used to correct the effects of covariates
and to test the independent factors. Logistic regression
was performed to estimate the OR and corresponding
95 % CI for dyslipidemia. Data were analyzed by soft-
ware SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). P
<0.05 (two-tailed) was considered to be statistically sig-
nificant for all analysis.
Results
The clinical and biochemical characteristics of the study
population
The clinical, biochemical and anthropometric character-
istics of the study population stratified by BNP quartiles
were summarized in Table 1. The subjects were divided
into four quartiles according to BNP levels (median
values: 7.0, 14.9, 30.6 and 65.5 pg/ml, respectively). The
prevalence of diabetes, hypertension, alcohol consump-
tion and smoking was comparable among four groups.
TSH, aspartate aminotransferase (AST), gamma-glutamyl
transpeptidase (GGT), eGFR, non-HDL and hemoglobin
A1c (HbA1c). Compared to the highest BNP quartile(Q4), the lower BNP quartile (Q1 and/or Q2) tended to
have younger age, lower Cr and HDL-C, and higher ala-
nine aminotransferase (ALT), BMI, TC, LDL-C and TAG
(P <0.05). The levels of UA followed a trend of biphasic
alteration with the elevation of BNP quartiles. BNP Q3
had significantly lower levels of UA compared to BNP Q1
and Q4 (P <0.05). These findings suggest that BNP levels
correlate with age, ALT, Cr, BMI, TC, LDL-C, HDL-C,
TAG and UA in this elderly population.
Association between plasma BNP levels with clinical
parameters
Table 2 shows the association of clinical characteristics
with plasma BNP levels by using univariable correlation
and multiple linear regression analysis. BNP as the
dependent variable was logarithmically transformed to
approximate normal distribution. In univariable correl-
ation, age was positively correlated with plasma BNP
(Spearman’s ρ = 0.361), whereas ALT, GGT, eGFR, TC,
TAG and non-HDL were negatively correlated with
plasma BNP (ρ = −0.327, −0.175, −0.117, −0.161, −0.184
and −0.170, respectively). In addition, BMI and LDL-C
were negatively associated with plasma BNP with mar-
ginally statistical significance. After stepwise multiple
regression adjusting for covariates (model R2 = 0.271,
P < 0.01), age was still positively associated with plasma
BNP (β = 0.051), whereas BMI, eGFR and non-HDL
were inversely associated with plasma BNP (β = −0.047,
−0.189 and −0.113, respectively). The data indicate that
BNP levels, in addition to age, BMI, non-HDL and
eGFR, were significantly associated with nonfasting lipid
parameters.
Dyslipidemia prevalence in individuals with different BNP
quartiles, and BNP levels in subjects with normal or
abnormal lipid levels
We next sought to explore the potential relationships
between BNP levels and dyslipidemia. As shown in
Fig. 1a, the prevalence of dyslipidemia gradually reduced
with the increase of BNP levels, including high TC, high
TAG and high LDL-C (*, P <0.01; **, P <0.001; compared
to BNP Q1). Figure 1b shows the BNP levels in normal
and abnormal lipid groups. The medians of BNP were
significantly lower in subjects with abnormal TC, LDL
and TAG than those with normal respective lipids (*, P
<0.01; **, P <0.001). These findings demonstrate that
higher BNP levels negatively correlated with the preva-
lence of nonfasting dyslipidemia.
Subjects with lower BNP quartiles (Q1-3) tend to have
raised risks for nonfasting dyslipidemia compared to the
highest BNP quartile (Q4)
Adjusted odds ratios (OR) with associated 95 % confi-
dence intervals (CI) of nonfasting dyslipidemia in the
Table 1 Difference in clinical characteristics of the population stratified by BNP quartiles
Variables BNP Q1 BNP Q2 BNP Q3 BNP Q4 P value
n = 170 n = 170 n = 170 n = 170
Men, n (%) 101 (59.4) 72 (42.4) 67 (39.4) 94 (55.3) <0.0001 a
Age, years 68 ± 5 68 ± 5 69 ± 6 70 ± 5 0.015 b
BNP, pg/ml 7.0 (5.5–8.0) 14.9 (11.2–17.3) 30.6 (24.3–37.4) 65.5 (53.9–83.5) -
BNP range, pg/ml 2.2–9.0 9.1–20.4 20.5–44.4 44.6–99.7 -
BMI, kg/m2 23.4 ± 4.1 24.4 ± 4.0 23.1 ± 4.3 22.5 ± 3.3 0.017 c
ALT, IU/L 28.5 ± 19.7 21.2 ± 13.0 18.9 ± 11.5 19.3 ± 21.0 <0.0001 d
AST, IU/L 27.0 ± 14.8 24.0 ± 12.1 22.5 ± 10.1 25.2 ± 20.8 0.232
GGT, IU/L 45.6 ± 58.0 30.1 ± 62.2 32.9 ± 48.6 34.7 ± 43.3 0.259
UA, mg/dL 5.5 ± 1.3 5.2 ± 1.4 5.1 ± 1.5 5.5 ± 1.6 0.04 e
Cr, mg/dL 0.78 ± 0.19 0.74 ± 0.18 0.76 ± 0.24 0.81 ± 0.25 0.0334 f
eGFR (ml/min/1.73 m2) 74.3 ± 25.9 73.6 ± 15.4 73.1 ± 19.9 70.2 ± 20.8 0.1860
TC, mg/dL 191.3 ± 37.3 200.1 ± 38.7 188.1 ± 34.2 179.6 ± 38.6 <0.0001 g
LDL-C, mg/dL 115.7 ± 35.0 119.0 ± 37.0 108.5 ± 33.2 107.4 ± 33.7 0.022 h
HDL-C, mg/dL 49.1 ± 11.5 55.7 ± 15.2 53.6 ± 13.8 53.0 ± 16.4 0.003 i
TAG, mg/dL※ 147.0 (107.3–223.0) 131.0 (91.75–184.0) 116.0 (91.0–170.0) 121.0 (83.0–158.3) <0.0001 j
non-HDL, mg/dL 142.2 ± 34.6 143.5 ± 37.1 133.8 ± 33.2 125.9 ± 33.3 0.081
TSH, mIU/L※ 1.6 (1.1–3.2) 1.5 (0.9–2.4) 1.5 (1.1–2.3) 1.5 (0.9–2.9) 0.714
HbA1c,% 6.0 ± 0.8 6.1 ± 1.3 6.1 ± 1.3 6.0 ± 1.1 0.3629
Diabetes, n (%) 49 (28.8) 36 (21.2) 33 (19.4) 38 (22.4) 0.182
Hypertension, n (%) 118 (69.4) 109 (64.1) 113 (66.5) 121 (71.2) 0.516
Current Smoker, n (%) 25 (14.7) 15 (8.8) 16 (9.4) 18 (10.6) 0.296
Current Drinker, n (%) 13 (7.6) 16 (9.4) 9 (5.3) 13 (7.6) 0.552
Data are expressed as mean ± SD for data with normal distribution, or median (25th, 75th percentiles) for data with skewed distribution, or number (percentage)
for categorical data. Chi-square test was used to compare categorical variables. The difference of continuous variables was compared using One-Way ANOVA, and
then Student-Newman-Keuls pairwise comparisons were performed if P <0.05. P values less than 0.05 are marked in bold. Note: (1) ※ Analysis was performed
using log-transformed data. (2) a. Q1 compared with Q2 and Q3 (P = 0.002, <0.0001); Q4 compare with Q2 and Q3 (P = 0.0017, 0.003); b. Q4 compared
with Q1, Q2 and Q3 (P = 0.03, 0.008, 0.073); c. Q2 compared with Q3 and Q4 (P = 0.027, 0.002); d. Q1 compared with Q2, Q3 and Q4 (P = 0.006, <0.0001,
<0.0001); e. Q3 compared with Q1 and Q4 (P = 0.025, 0.016); f. Q4 VS Q2, P < 0.05; g. Q2 compared with Q3 and Q4 (P = 0.010, <0.0001); Q1 compared
with Q4 (P = 0.015); h. Q2 compared with Q3 and Q4 (P = 0.016, 0.009); i. Q1 compared with Q2, Q3 and Q4 (P < 0.0001,0.013,0.036); j. Q1 compared with
Q2, Q3 and Q4 (P = 0.006, <0.0001, <0.0001)
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ence. In model 1 (adjusted for smoking, hypertension,
drinking, diabetes, HbA1c, TSH, ALT, AST, GGT and
UA), the risks of hypercholesterolemia, hyper-LDL-emia
and hypertriglyceridemia were significantly elevated in
the BNP Q1 group, while the risks for hypertriglyc-
eridemia was progressively reduced in BNP Q2 and Q3
group. In model 2 (additionally adjusted for eGFR) and
model 3 (further adjustment for age and BMI), the
results were similar to model 1. In model 3, individ-
uals in the BNP Q1 and Q2 quartiles had increased
risks for nonfasting dyslipidemia (OR [95 % CI] for
BNP Q1: TC 2.042 [1.192–3.500], P = 0.009; Q2: TC
2.316 [1.372–3.911], P = 0.002; BNP Q1: TAG 3.938
[2.013–7.702], P < 0.0001; Q2: TAG 2.134 [1.051–
4.336], P = 0.036). The OR for hyper-LDL-emia in the
BNP Q1 quartile reached marginally statistical signifi-
cance (OR [95 % CI]: 1.778 [0.986–3.203], P = 0.056).These findings showed that subjects with higher BNP
levels tended to have reduced risks for nonfasting
dyslipidemia, especially for hypercholesterolemia and
hypertriglyceridemia.
Discussion
In this cross-sectional study, we found that nonfasting
dyslipidemia in the elderly Japanese population nega-
tively correlated with BNP levels within the physiological
range. The elderly people with the lowest BNP quartile
were prone to have obviously elevated risks for nonfast-
ing hypercholesterolemia and hypertriglyceridemia, as
opposed to subjects with higher BNP quartiles. Although
the correlation between BNP and lipid profiles was
found but was not potent enough in linear analysis
model, results from multiple regression analysis further
supported this association independent of several clinical
variables.
Table 2 Linear and multiple regression analysis of association between metabolic parameters and BNP levels (Log BNP) in the
subjects
Variables Univariate correlation Multivariate regression
ρ coefficient P value β coefficient P value
Gender (men,1; women, 0) −0.028 0.602
Age (years) 0.361 <0.001 0.051 <0.001
BMI (kg/m2) −0.128 0.054 −0.047 0.001
ALT (IU/L) −0.327 <0.001
AST (IU/L) −0.089 0.093
GGT (IU/L) −0.175 0.001
UA (mg/dL) 0.035 0.563
Cr (mg/dL) 0.054 0.306
eGFR (ml/min/1.73 m2) −0.117 0.027 −0.189 0.005
TC (mg/dL) −0.161 0.007
LDL-C (mg/dL) −0.119 0.054
HDL-C (mg/dL) 0.050 0.403
Log TAG (mg/dL) −0.184 0.001
non-HDL (mg/dL) −0.170 0.008 −0.113 <0.001
Log TSH (mIU/L) −0.021 0.650
HbA1c (%) 0.125 0.321
Diabetes (yes = 1; no = 0) −0.045 0.481
Hypertension (yes = 1; no = 0) 0.012 0.621
Smoking (yes = 1; no = 0) 0.008 0.724
Drinking (yes = 1; no = 0) 0.005 0.565
P values less than 0.05 are marked in bold
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tide (NT-proBNP) which is equimolarly released into
circulation with BNP, has also been used widely as a sur-
rogate biomarker for BNP. Recently, the levels of fasting
LDL-C and TAG have been demonstrated to be inversely
associated with NT-proBNP and followed a biphasic pat-
tern, with the turning point at 100 pg/ml [21]. The linearFig. 1 a The prevalence of abnormal lipid profiles stratified by different
points of dyslipidemia were defined as described in the methods. Chi-sq
BNP levels between normal and abnormal groups according to lipid pro
range, and the bars indicate the lowest or highest BNP levels. Boxes in
boxes represent patients with normal lipid profiles (Mann–Whitney U tes
group). Note that numbers on the right vertical axis are correspondingassociations between lipids and NT-proBNP became not
obvious for those whose NT-proBNP levels were higher
than 100 pg/ml. This study also established a positive
correlation of HDL-C level with NT-proBNP, which is a
little different from our results. Although the linear
trend between HDL-C and BNP was not observed in the
current population, subjects with BNP Q1 had markedlyBNP quartiles (*, P <0.01 vs. Q1; **, P <0.001 vs. Q1). The cut-off
uare test was used to compare the difference. b The difference of
files. The lines denote the median, the boxes represent interquartile
grey denote patients with abnormal lipid profiles, whereas open
t was used. *, P <0.01 vs. normal group; **, P <0.001 vs. normal
to log-transformed values on the left axis
Fig. 2 Logistic regression to evaluate the OR and 95 % CI for dyslipidemia in BNP quartiles (Q1, Q2, Q3) compared to BNP Q4. Model 1: adjusted
for smoking, hypertension, drinking, diabetes, HbA1c, TSH, ALT, AST, GGT and UA; Model 2: Model 1 + eGFR; Model 3: Model 2 + age + BMI
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Nevertheless, both studies have consistently confirmed
increased risks of dyslipidemia for individuals with low
BNP levels regardless of the ethnicity or fasting status.
The mechanisms for the association between BNP
levels and lipid metabolism can be ascribed to several
reasons. BNP levels are determined by the dynamic bal-
ance of production and clearance. Firstly, several
humoral factors are involved in the modulation of BNP
secretion, including glucagon-like peptide-1 (GLP-1) [1].
GLP-1 is well-recognized as an intestinal hormone with
significantly reduced levels in obese patients [22]. GLP-1
directly promotes the secretion of ANP in atrial cardio-
myocytes through GLP-1 receptor [23]. Although it re-
mains unknown whether the similar phenomenon exists
in BNP secretion, another clinical study observed that
ANP and BNP both were elevated after GLP-1 analogue
treatment [24]. Chronic inflammation triggered by rela-
tive adipocyte hypoxia is a hallmark in metabolic disor-
ders [25]. As a well-known factor involved in insulin
resistance, tumor necrosis factor-α (TNF-α) also impairs
GLP-1 secretion from the intestinal L-cells [26]. This is
in accord with the clinical observation that patients with
fatty liver disease or obesity have low levels of GLP-1
[27, 28]. Secondly, plasma BNP is cleared through
receptor-mediated degradation and extracellular protease-
dependent pathways. Natriuretic peptide clearance recep-
tor (NPR-C) is a pseudo-receptor which binds the BNP
for internalization and degradation. Increased NPR-C in
the adipose tissue accelerates the clearance of BNP in the
obese individuals [29, 30]. In addition, insulin-degrading
enzyme (IDE) and dipeptidyl peptidase-4 (DPP-4) have
been demonstrated to inactivate BNP in a protease-
dependent manner [31, 32]. Recently, it has been shown
that the activity of IDE in the liver is enhanced in a diet-
induced obesity model [33]. DPP-4 hyperactivity has been
observed in morbidly obese patients [34, 35]. Thus, mul-
tiple mechanisms are responsible for the BNP handicap
phenomenon in metabolic syndrome. Thirdly, BNP is
dependent on renal function for clearance [36]. So, it isreasonable that age-dependent BNP elevation may be
partly due to the decline of eGFR with aging. The age-
related elevation of BNP might be a protective mechanism
for favorable lipid metabolism. The U-shaped alteration of
UA levels from the lowest to highest BNP quartiles
(Q1-Q4) may be the consequence of reduced meta-
bolic syndrome together with elevated eGFR.
In our study, subjects within BNP Q1 had higher ALT
levels than individuals with BNP Q2-4, which may be
caused by increased prevalence of fatty liver diseases.
Similarly, the mean BMI in BNP Q2 group was markedly
higher than BNP Q3-4. From the observation that BNP
is inversely related with visceral fat and liver fat [12], we
may extrapolate that high prevalence of metabolic hep-
atic abnormalities and dyslipidemia in people with low
levels of BNP are in part caused by ectopic fat accumula-
tion. Interestingly, BNP also functions to increase the
feeling of satiety. People with low levels of BNP are pre-
disposed to have increased appetite which results in
obesity [37]. Higher ALT and insulin resistance have
long been considered as a risk factor for high TAG levels
[38]. In addition, BNP levels have been shown to be
negatively correlated with insulin resistance irrespective
of obesity [39]. Insulin resistance in the liver not only
promotes the de novo hepatic lipogenesis but also re-
duces the degradation of TAG-enriched lipoproteins,
leading to both fasting and postprandial hypertriglyc-
eridemia [40]. Insulin sensitivity index has repeatedly
been documented to be associated with increased chol-
esterol synthesis in a hyperglycemia-independent man-
ner [41, 42].
Traditionally, lipid levels have been determined in the
fasting state mainly due to the reduced variability than
random sampling. The evidences from a large number
of epidemiological studies repeatedly support the risk-
predictive values of nonfasting lipids, especially nonfast-
ing TAG, for CVD [18]. Individuals with hyperglyceride-
mia are prone to produce strongly atherogenic
lipoproteins, such as cholesterol-rich remnant-like lipo-
proteins and small dense LDL particles [43]. The finding
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hyperglyceridemia links with the lowest BNP Q1 quartile
(2.2–9.9 pg/ml) is consistent with another recently pub-
lished observation [21]. Therefore, individuals with lower
BNP levels may have increased risk for CVD events
regardless of the races, age, gender and BMI. As men-
tioned earlier, higher levels of BNP correlates with in-
creased vascular events and all-cause mortality in
Justification for the Use of Statins in Prevention: An
Intervention Trial Evaluating Rosuvastatin (JUPITER)
[3], which is inconsistent with our observation. This dis-
crepancy might be caused by the eligible participants
involved in JUPITER who had LDL-C <130 mg/dL.
Therefore, the study has excluded people with lower
BNP levels which often link with dyslipidemia. It should
be acknowledged that people with higher BNP often
have increased risks for cardiovascular events, which in-
cludes older age, myocardial injuries and elevated eGFR.
Thus, our study doesn’t imply that higher BNP corre-
lates with better clinical outcome.
However, several limitations exist in our current study.
Firstly, data on waist circumference which reflect vis-
ceral obesity are lacking. Secondly, insulin resistance
which is a predisposing factor for dyslipidemia may be
associated with BNP levels. The insulin resistance index
and glucose metabolism are unknown in the study.
Thirdly, our cross-sectional observation is unable to es-
tablish potential cause-effect relationship between BNP
levels and dyslipidemia. In addition, the sample size of
the population is not large enough. Thus, our findings
require further studies to identify the relationship
between plasma BNP levels and lipid profiles.Conclusions
In conclusion, the current cross-sectional study provides
further evidence about the metabolic risks of low BNP
levels in the elderly. Elderly individuals with lower BNP
levels tend to have higher prevalence of nonfasting dys-
lipidemia. Thus, it warrants further investigation whether
BNP could serve as a biomarker or have therapeutic impli-
cations for dyslipidemia in the elderly people.Abbreviations
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